Lower urinary tract symptoms among male patients on hemodialysis: Prospective and multi-central cross-sectional study
SAGE Open Medicine · 2024-01 · 12
DOI: 10.1177/20503121241263302 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift SAGE Open Medicine, online erschienen am 30.07.2024. Verfasst von Faris Abushamma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Lower urinary tract symptoms are common and can significantly impact quality of life, especially in men with co-morbidities and end-stage renal disease. The presence of lower urinary tract symptoms affect the quality of life of patients on hemodialysis.
Objectives
The purpose of this study is assessing the presence and severity of lower urinary tract symptoms among male patients on hemodialysis. Factors that may exacerbate lower urinary tract symptoms were assessed and studied. The impact of lower urinary tract symptoms on quality of life was also identified.
Methods
A prospective, multi-central, and cross-sectional study of male patients on hemodialysis was conducted. Demographics, clinical data, and core lower urinary tract symptoms score questionnaire were all collected. A correlation has been made between all variables.
Results
One hundred forty-five patients were enrolled. Eighty-seven percent of hemodialysis patients had at least one storage symptom, and 85% had at least one voiding symptom. The prevalence of storage symptoms (frequency, nocturia, urgency, and urgency incontinence) was found to be 3%, 70%, 44%, and 12%, respectively. The voiding symptoms were mainly weak stream, straining, and incomplete emptying, which were found in 60%, 43%, and 36%, respectively. Fifteen percent of the cohort had a negatively significant impact on their quality of life. The absence of voiding symptoms was statistically linked to a better quality of life ( p < 0.05). Hemodialysis patients who are over 60 years old, smokers, or obese were found to be significantly more likely to report storage symptoms (18%, 9%, and 79%, respectively; p < 0.05). Bladder pain was significantly correlated to the dialysis duration of more than 24 months ( p < 0.05).
Conclusion
Storage and voiding lower urinary tract symptoms are common among hemodialysis male patients with a minor impact on their quality of life. Age, smoking, and obesity are major risks of exaggerating such symptoms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
- Department of Urology, An-Najah National University Hospital, Nablus, Palestine.
- Department of Nephrology, An-Najah National University Hospital, Nablus, Palestine.
- Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK.
ORCID-Profile: Faris Abushamma
Zitieren
APA
Abushamma, F., Zidan, E., Douglass, Z. E., Jaber, A., Nazzal, Z., Hamdan, Z. I., Ktaifan, M., & Hashim, H. (2024). Lower urinary tract symptoms among male patients on hemodialysis: Prospective and multi-central cross-sectional study. SAGE Open Medicine, 12. https://doi.org/10.1177/20503121241263302
Vancouver
Abushamma F, Zidan E, Douglass ZE, Jaber A, Nazzal Z, Hamdan ZI, et al. Lower urinary tract symptoms among male patients on hemodialysis: Prospective and multi-central cross-sectional study. SAGE Open Medicine. 2024;12. doi:10.1177/20503121241263302
BibTeX
@article{Abushamma2024,
author = {Abushamma, Faris and Zidan, Enas and Douglass, Zainab E and Jaber, Anas and Nazzal, Zaher and Hamdan, Zakaria I and Ktaifan, Mahfouz and Hashim, Hashim},
title = {Lower urinary tract symptoms among male patients on hemodialysis: Prospective and multi-central cross-sectional study},
journal = {SAGE Open Medicine},
year = {2024},
volume = {12},
doi = {10.1177/20503121241263302}
}
EUVIMED